Drug Trial Radar · NCT00847912
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
954
Actual
Start
Jun 26, 2009
Primary completion
Jun 28, 2013
Study completion Jul 30, 2016
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Feb 19, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to see if 5-fluorouracil (5-FU) skin cream can prevent the growth of new skin cancers on the face and ears. The cost of trying to prevent skin cancer will be compared to the usual cost of treating skin cancer. Participants are being asked to be a part of this study because the participants have been treated for two or more skin cancers within the past five (5) years. At least one of these cancers occurred on the face or ears. Having had two or more skins cancers in the past 5 years makes it likely that participants will develop additional skin cancers in the future. Exposure to ultraviolet radiation from the sun or artificial sources such as tanning beds is a major cause of basal cell and squamous cell carcinoma of the skin. Using lotions, creams, or gels that contain sunscreens can help protect the skin from premature aging and damage that may lead to skin cancer. The 5-FU skin cream used in this study is FDA-approved to treat some types of skin cancers and spots that might become skin cancer. However, 5-FU skin cream has never been studied to see if it can prevent skin cancer. This drug is not approved by the FDA for how it will be used in this study. In this study, one half of the patients will use the 5-FU cream and the other half will use a skin cream that looks identical to the 5-FU cream but does not have 5-FU or any other active drug in it. Approximately twelve VA medical centers will work together in this study. About one thousand (1000) patients will be in this study. The study is sponsored by the U.S. Department of Veterans Affairs Cooperative Studies Program.
Conditions
- Carcinoma, Basal Cell
- Carcinoma, Squamous Cell
- Skin Neoplasms
- Skin Diseases
- Neoplasms, Basal Cell
- Neoplasms, Squamous Cell
- Carcinoma
Interventions
5-fluorouracilDrug
Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate "cool-down" treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the "cool-down" routine will be followed, but 5-FU will be stopped.
Placebo, vehicle controlDrug
Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate "cool-down" treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the "cool-down" routine will be followed, but vehicle control cream will be stopped.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is PerformedTime frame: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years
- Hazard Ratio for Surgically Treated KCTime frame: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
VA Palo Alto Health Care System, Palo Alto, CA
Palo Alto, California
VA San Diego Healthcare System, San Diego, CA
San Diego, California
VA Eastern Colorado Health Care System, Denver, CO
Denver, Colorado
Bay Pines VA Healthcare System, Pay Pines, FL
Bay Pines, Florida
Miami VA Healthcare System, Miami, FL
Miami, Florida
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, Georgia
Edward Hines Jr. VA Hospital, Hines, IL
Hines, Illinois
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota
Durham VA Medical Center, Durham, NC
Durham, North Carolina
Philadelphia VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania
Providence VA Medical Center, Providence, RI
Providence, Rhode Island
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.